作为船用板材专业化加工的重点项目，秉诺二期中厚板船板加工项目总投资5.5亿元，新建钢材预处理 全自动生产线、抛丸生产线及喷漆设备等设施，采用国际先进抛丸、喷漆技术开展专业化表面处理，有 效提升产品表面质量与使用寿命，设计年产能50万吨，达产后预计年营业收入超20亿元。 （来源：唐山劳动日报） 本报讯 （刘天玥、郭雨）近日，唐山海港经济开发区秉诺二期中厚板船板加工项目投入试生产，填补 了区域船板制造空白。 为保障项目高效推进，海港区通过优化审批办理流程、强化要素供给保障等一系列举措，持续畅通政企 沟通渠道、提升政务服务效能。在此背景下，该项目以股权收购模式"腾笼换鸟"，盘活147亩闲置地块 及配套设施，省去新增征地流程，让沉睡资源精准匹配产业需求。同时，依托与敬业华西特钢、唐山中 厚板公司相邻的地缘优势，构建"本地钢材-本地加工-本地结算"产业链闭环，有效降低物流成本、提升 钢铁配套率，助力"海港制造"对接国内外高端造船市场。 ...

中新网佳木斯12月27日电(姜辉闫瀛锟梁晨)近日，同江市本土速冻"绿油豆"通过浮箱固冰通道顺利出口 至俄罗斯哈巴罗夫斯克，标志着依托"黑土地+口岸"的双重优势，同江已逐步形成从种植、加工到出口 完整产业闭环，昔日的"通道经济"正在向附加值更高、带动性更强的"落地经济"转型。 同江晶都冷链物流有限公司厂房里，工人们熟练地将一箱箱速冻"绿油豆"整齐码放进俄罗斯货车里。负 责此次运输的俄罗斯司机罗曼，已从事5年货物运输工作，第一次把车从俄罗斯开到了中国同江。 "我从哈巴罗夫斯克来的，距离同江350公里，时间用了不到一天。"罗曼说："浮箱固冰通道方便了俄罗 斯和中国之间的交通。在同江口岸，我看到了很多挂着中国牌照的车辆，希望俄罗斯的车辆也会越来越 多，这意味着两国的贸易往来越来越好。" 工人将一箱箱同江本地速冻"绿油豆"整齐码放进俄罗斯货车。同江市委宣传部供图 同江本地速冻"绿油豆"被通过浮箱固冰通道运往俄罗斯。同江市委宣传部供图 出口的速冻"绿油豆"，产自同江晶都冷链物流有限公司的450亩种植基地。该公司今年5月播种，7月采 收，采用"水肥一体化+大垄双行"技术确保源头品质。豆角田间采摘后立即进入速冻加工与冷链储存 ...

Core Viewpoint - The transfer of control and asset injection into Rhine Biotech is seen as a crucial move to address the company's operational challenges and enhance its market position following the departure of its founder due to regulatory penalties [1][2]. Group 1: Control Change and Asset Injection - Rhine Biotech's controlling shareholder, Qin Benjun, plans to transfer 8.09% of shares to Guangzhou Defu Nutrition for 645.6 million yuan, relinquishing 25.5% of voting rights [1][3]. - After the transfer, Guangzhou Defu Nutrition will become the controlling shareholder, with Hou Ming and Li Zhenfu as joint actual controllers [1][3]. - The company will also acquire an 80% stake in Beijing Jinkangpu Food Technology through a share issuance, marking a significant asset injection [1][5]. Group 2: Financial Performance and Challenges - For the first three quarters of 2025, Rhine Biotech reported revenues of 1.272 billion yuan, an increase of 8.73%, but a net profit of 70.4 million yuan, down 30.73% year-on-year [1][8]. - Qin Benjun faces significant financial pressure, with over 65% of his shares pledged and a financing balance of 207 million yuan due within six months [1][8]. Group 3: New Business Direction - The acquisition of Beijing Jinkangpu, a leader in food nutrition fortifiers, allows Rhine Biotech to enter the nutrition health sector, expanding its business model [7][10]. - Beijing Jinkangpu's revenue for 2023 to the first nine months of 2025 was 370 million yuan, 432 million yuan, and 338 million yuan, respectively [9]. - The transaction is expected to create a closed-loop industry chain from raw materials to formulation solutions, enhancing operational stability and risk resilience for Rhine Biotech [10]. Group 4: Market Reaction - Following the announcement of the control change and restructuring plan, Rhine Biotech's stock price hit the daily limit, closing at 9.57 yuan per share, a 10% increase [11].

Core Viewpoint - Rhine Biotech (002166) has officially disclosed its asset restructuring and control change plan after a 10-day trading suspension, intending to issue shares to Guangzhou Defu Nutrition Investment Partnership and change its controlling shareholder to Guangzhou Defu Nutrition [1][2] Group 1: Share Transfer and Control Change - The control change framework agreement was signed on December 22, where Qin Benjun, the controlling shareholder, will transfer 8.09% of shares to Guangzhou Defu Nutrition and relinquish 25.50% of voting rights while retaining 3% [2] - After the transaction, Guangzhou Defu Nutrition will hold 8.09% of shares and 11.17% of voting rights, while Qin Benjun will retain 28.50% of shares and 4.14% of voting rights [2] - The total transaction price is estimated at 646 million yuan, with a transfer price of 10.76 yuan per share, representing a premium of 23.68% compared to the closing price of 8.70 yuan before the suspension [2] Group 2: Strategic Intent and Business Expansion - Guangzhou Defu Nutrition, established on December 2, 2025, is an investment company focused on the healthcare sector, managing nearly 24 billion yuan in healthcare assets [3] - Rhine Biotech aims to leverage Defu Capital's resources to enhance its investment and acquisition capabilities in the healthcare sector, creating a comprehensive health ecosystem [3] - The company has signed agreements to acquire 80% of Beijing Jinkangpu, a leading enterprise in the field of nutritional fortifiers, thereby expanding its business into the nutritional fortifier formulation sector [4][6] Group 3: Financial Performance of Beijing Jinkangpu - As of September 2023, Beijing Jinkangpu reported total assets of 593 million yuan and net assets of 535 million yuan, with revenues of 338 million yuan and a net profit of 40.33 million yuan for the first three quarters of 2025 [4]

Core Viewpoint - The stock of Rhine Biotech (002166.SZ) resumed trading and hit the daily limit, closing at 9.57 yuan, a 10.00% increase, following the announcement of a change in control and related agreements [1]. Group 1: Control Change Agreements - The controlling shareholder Qin Benjun signed several agreements with Guangzhou Defu Nutrition Investment Partnership, including a framework agreement for control change and a share transfer agreement, transferring 60 million shares (8.09% of total shares) and relinquishing voting rights for 189,141,310 shares (25.50% of total shares) [2][8]. - After the transfer, Guangzhou Defu Nutrition will become the controlling shareholder, with Hou Ming and Li Zhenfu as the joint actual controllers of the company [4][8]. Group 2: Share Transfer Details - The share transfer price was set at 10.76 yuan per share, totaling 645.6 million yuan, inclusive of all applicable taxes [3]. - Post-transfer, Qin Benjun will retain voting rights for 22,248,282 shares (3.00% of total shares) [2][8]. Group 3: Asset Purchase and Fundraising - The company plans to issue shares to acquire 80% of Beijing Jinkangpu's equity from Defu Jinkangpu and Xiamen Defu Jinkangpu, and to raise funds for purchasing additional shares from individual shareholders [4][6]. - The final transaction price for the assets will be based on an evaluation report from a qualified asset appraisal agency [5]. - The company aims to expand its business into the nutritional fortifier sector, enhancing its operational stability and risk resistance [6][7]. Group 4: Financial Performance of Target Company - For the fiscal year 2024 and the first three quarters of 2025, Beijing Jinkangpu reported revenues of 431.82 million yuan and 337.65 million yuan, respectively, with net profits of 70.27 million yuan and 40.33 million yuan, and a return on equity of 14.33% and 7.60% [7].

Group 1 - The company announced a control change agreement where Qin Benjun will transfer 60 million shares (8.09%) to Guangzhou Defu Nutrition and relinquish voting rights for 189,141,310 shares (25.50%), retaining voting rights for 22,248,282 shares (3.00%) [1] - Following the completion of the share transfer and board restructuring, Guangzhou Defu Nutrition will become the controlling shareholder, with Hou Ming and Li Zhenfu as the joint actual controllers [1] - The company plans to acquire 80% of Beijing Jinkangpu Food Technology Co., Ltd. through a share issuance to Defu Jinkangpu Holdings and Xiamen Defu Jinkangpu Investment [1] Group 2 - The target company specializes in the formulation, production, testing, sales, and technical services of food nutrition fortifiers, serving various sectors including dairy products and health foods [2] - The target company is a leading enterprise in the food nutrition fortifier industry, supplying to numerous infant formula manufacturers [2] - The acquisition will enhance the company's business structure, creating a closed-loop industry chain from raw materials to formulation solutions, thereby improving operational stability and risk resistance [2] Group 3 - The company's stock will resume trading on December 24, 2025 [3]

Group 1 - The company announced a change in control agreement where Qin Benjun will transfer 60 million shares (8.09%) to Guangzhou Defu Nutrition and relinquish voting rights for 189,141,310 shares (25.50%), retaining voting rights for 22,248,282 shares (3.00%) [1] - Following the completion of the share transfer and board restructuring, Guangzhou Defu Nutrition will become the controlling shareholder, with Hou Ming and Li Zhenfu as the joint actual controllers of the company [1] - The company plans to acquire 80% of Beijing Jinkangpu Food Technology Co., Ltd. through a share issuance to Defu Jinkangpu Holdings and Xiamen Defu Jinkangpu Investment [1] Group 2 - The target company specializes in the formulation, production, testing, sales, and technical services of food nutrition fortifiers, serving various sectors including dairy products and functional beverages [2] - The target company is a leading enterprise in the food nutrition fortifier industry, supplying to numerous infant formula manufacturers [2] - The acquisition will enhance the company's business structure, making it more diversified and improving operational stability and risk resistance [2] Group 3 - The company's stock will resume trading on December 24, 2025 [3]

Group 1 - The controlling shareholder of the company, Qin Benjun, plans to transfer 60 million shares (8.09% of total share capital) to Guangzhou Defu Nutrition and will relinquish voting rights for 189,141,310 shares (25.50% of total share capital), retaining 3.00% voting rights [1] - Guangzhou Defu Nutrition will become the controlling shareholder of the company, with Hou Ming and Li Zhenfu as the joint actual controllers [1] - The company intends to acquire 80% of Beijing Jinkangpu Food Technology Co., Ltd. through a share issuance and raise additional funds for purchasing 15.50% equity from natural shareholders Li Yang and Song Jun, as well as covering intermediary fees, transaction taxes, and supplementing working capital [1] Group 2 - The target company specializes in the formulation, production, testing, sales, technological innovation, and services of food nutrition fortifiers, widely used in dairy products, functional beverages, complementary foods, medical foods, and health foods [2] - The target company is a leading enterprise in the food nutrition fortifier sector, supplying nutrition fortifiers to numerous infant formula manufacturers both domestically and internationally [2] - The acquisition will allow the listed company to expand its industrial chain into the nutrition fortifier compounding field, creating a closed-loop from upstream raw materials to downstream formulation solutions, enhancing business synergy and stability [2]

Group 1 - The core point of the article is that Rhine Biology (002166.SZ) is undergoing significant changes in its ownership structure and is planning to acquire a majority stake in Beijing Jinkangpu Food Technology Co., Ltd. [1] - The controlling shareholder, Qin Benjun, intends to transfer 60 million shares (8.09% of total share capital) to Guangzhou Defu Nutrition and will relinquish voting rights for 189,141,310 shares (25.50% of total share capital), retaining only 3.00% voting rights [1] - Following this transfer, Guangzhou Defu Nutrition will become the controlling shareholder, with Hou Ming and Li Zhenfu as the joint actual controllers of the company [1] Group 2 - The target company specializes in the formulation, production, testing, sales, technological innovation, and services of food nutrition fortifiers, which are widely used in dairy products, functional beverages, complementary foods, medical foods, and health foods [2] - The target company is a leading enterprise in the food nutrition fortifier sector, supplying nutrition fortifiers to numerous infant formula manufacturers both domestically and internationally [2] - This acquisition will allow the listed company to expand its industrial chain into the nutrition fortifier compounding field, creating a closed-loop from upstream raw materials to downstream formulation solutions, enhancing business synergy and stability [2]

Core Viewpoint - The company, Rhein Biotech, plans to acquire an 80% stake in Beijing Jinkangpu Food Technology Co., Ltd., a leading provider of nutritional fortifiers for infant formula, thereby expanding its industry chain into the nutritional fortifier compounding sector [1] Group 1: Acquisition Details - Rhein Biotech intends to issue shares to Defu Jinkangpu and Xiamen Defu Jinkangpu to purchase their combined 80% stake in Beijing Jinkangpu [1] - The transaction is still pending completion of auditing and evaluation work [1] Group 2: Strategic Implications - The acquisition will create a closed-loop industry chain from upstream raw materials to downstream formulation solutions in the nutritional fortifier sector [1] Group 3: Shareholder Changes - On December 22, Guangzhou Defu Nutrition signed an agreement with the company's original controlling shareholder, Qin Benjun, to transfer 8.09% of shares and relinquish voting rights for 25.5% of shares, retaining voting rights for 3% [1] - Following the share transfer and board restructuring, Guangzhou Defu Nutrition will become the controlling shareholder, with Hou Ming and Li Zhenfu as co-controlling persons [1] - Guangzhou Defu Nutrition, Defu Jinkangpu, and Xiamen Defu Jinkangpu are related entities under common control [1] Group 4: Stock Resumption - The company's stock will resume trading on December 24 [1]